Flagyl Filmuhúðuð tafla 400 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

flagyl filmuhúðuð tafla 400 mg

sanofi-aventis norge as - metronidazolum inn - filmuhúðuð tafla - 400 mg

Flagyl Leggangastíll 500 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

flagyl leggangastíll 500 mg

sanofi-aventis norge as - metronidazolum inn - leggangastíll - 500 mg

Holoxan Innrennslisstofn, lausn 500 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

holoxan innrennslisstofn, lausn 500 mg

baxter medical ab* - ifosfamidum inn - innrennslisstofn, lausn - 500 mg

Holoxan Innrennslisstofn, lausn 2000 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

holoxan innrennslisstofn, lausn 2000 mg

baxter medical ab* - ifosfamidum inn - innrennslisstofn, lausn - 2000 mg

Holoxan Innrennslisstofn, lausn 1000 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

holoxan innrennslisstofn, lausn 1000 mg

baxter medical ab* - ifosfamidum inn - innrennslisstofn, lausn - 1000 mg

Trimbow Evrópusambandið - íslenska - EMA (European Medicines Agency)

trimbow

chiesi farmaceutici s.p.a. - beclometasone dipropionate, formóteróli fúmarat tvíhýdrat, Þannig brómíð - lungnasjúkdómur, langvarandi hindrandi - lyf til veikindi öndunarvegi sjúkdómum, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.